Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy.

ABSTRACT:

Background

Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor treatment for HER2-positive breast cancer have led to greater use of non-anthracycline regimens that are associated with lower cardiotoxicity risk, raising into question the need for frequent cardiotoxicity surveillance for these patients. This study seeks to evaluate whether less frequent cardiotoxicity surveillance (every 6 months) is safe for patients receiving a non-anthracycline HER2-targeted treatment regimen.

Methods/design

We will enroll 190 women with histologically confirmed HER2-positive breast cancer scheduled to receive a non-anthracycline HER2-targ

SUBMITTER: Yu AF 

PROVIDER: S-EPMC9996968 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature